WEKO3
アイテム
{"_buckets": {"deposit": "d37ee2b8-972f-4c50-a2e9-76e64af2caa1"}, "_deposit": {"created_by": 1, "id": "46149", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "46149"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00046149", "sets": ["1"]}, "author_link": ["459486", "459491", "459484", "459479", "459481", "459485", "459489", "459488", "459487", "459490", "459483", "459480", "459482"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2011-08", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "8", "bibliographicPageEnd": "1328", "bibliographicPageStart": "1322", "bibliographicVolumeNumber": "52", "bibliographic_titles": [{"bibliographic_title": "Journal of Nuclear Medicine"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Recently, we developed [methyl-11C]4\u0027-thiothymidine (11C-4DST) as an in vivo cell proliferation marker. The present study was performed to determine the safety, distribution, radiation dosimetry, and initial brain tumor imaging of 11C-4DST in humans. Methods: Multiorgan biodistribution and radiation dosimetry of 11C-4DST were assessed in 3 healthy humans, who underwent 2-h whole-body PET scanning. Radiation dosimetry was estimated from the residence times of source organs using the OLINDA program. Six brain tumor patients underwent dynamic 11C-4DST scans with arterial blood sampling. These patients were also evaluated with 11C-methionine PET on the same day (n = 4) as, or 3 wk before (n = 2), 11C-4DST PET studies. Metabolites in plasma and urine samples were analyzed by high-performance liquid chromatography. Breakdown of the blood\u0026#8211;brain barrier in tumor tissue was confirmed by gadolinium-enhanced T1-weighted MRI. Results: There were no serious adverse events in any subjects at any time during the study period. 11C-4DST PET demonstrated selective uptake in the bone marrow, which has a high rate of proliferation. In addition, high-level uptake was also seen in the liver. The highest absorbed organ dose was in the urinary bladder wall (17.6 muGy/MBq). The estimated effective dose for 11C-4DST was 4.2 muSv/MBq. 11C-4DST showed little uptake in normal brain tissues, resulting in low background activity for imaging of brain tumors. In contrast, 11C-4DST PET demonstrated rapid uptake in aggressive tumor masses, whereas no signal of 11C-4DST was seen in clinically stable disease in which 11C-methionine uptake was high. The distribution pattern of 11C-methionine in tumor regions was not always identical to that of 11C-4DST. Analysis of plasma samples by high-performance liquid chromatography indicated that more than 60% of the radioactivity was present as unchanged 11C-4DST at 20 min. Conclusion: The initial findings of the present study in a small group of patients indicated that 11C-4DST PET is feasible for imaging of brain tumors. Dosimetry and pharmacologic safety were acceptable at the dose required for adequate PET images.", "subitem_description_type": "Abstract"}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0161-5505", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Toyohara, Jun"}], "nameIdentifiers": [{"nameIdentifier": "459479", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nariai, Tadashi"}], "nameIdentifiers": [{"nameIdentifier": "459480", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sakata, Muneyuki"}], "nameIdentifiers": [{"nameIdentifier": "459481", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oda, Keiichi"}], "nameIdentifiers": [{"nameIdentifier": "459482", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishii, Kenji"}], "nameIdentifiers": [{"nameIdentifier": "459483", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Irie, Toshiaki"}], "nameIdentifiers": [{"nameIdentifier": "459484", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saga, Tsuneo"}], "nameIdentifiers": [{"nameIdentifier": "459485", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kubota, Kazuo"}], "nameIdentifiers": [{"nameIdentifier": "459486", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishiwata, Kiichi"}], "nameIdentifiers": [{"nameIdentifier": "459487", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "豊原 潤", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "459488", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "成相 直", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "459489", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "入江 俊章", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "459490", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "佐賀 恒夫", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "459491", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Whole-Body Distribution and Brain Tumor Imaging with 11C-4DST: a Pilot Study", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Whole-Body Distribution and Brain Tumor Imaging with 11C-4DST: a Pilot Study"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/46149", "pubdate": {"attribute_name": "公開日", "attribute_value": "2011-07-25"}, "publish_date": "2011-07-25", "publish_status": "0", "recid": "46149", "relation": {}, "relation_version_is_last": true, "title": ["Whole-Body Distribution and Brain Tumor Imaging with 11C-4DST: a Pilot Study"], "weko_shared_id": -1}
Whole-Body Distribution and Brain Tumor Imaging with 11C-4DST: a Pilot Study
https://repo.qst.go.jp/records/46149
https://repo.qst.go.jp/records/4614945a23a60-7ce1-46e8-b90d-9ef787adb449
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2011-07-25 | |||||
タイトル | ||||||
タイトル | Whole-Body Distribution and Brain Tumor Imaging with 11C-4DST: a Pilot Study | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Toyohara, Jun
× Toyohara, Jun× Nariai, Tadashi× Sakata, Muneyuki× Oda, Keiichi× Ishii, Kenji× Irie, Toshiaki× Saga, Tsuneo× Kubota, Kazuo× Ishiwata, Kiichi× 豊原 潤× 成相 直× 入江 俊章× 佐賀 恒夫 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Recently, we developed [methyl-11C]4'-thiothymidine (11C-4DST) as an in vivo cell proliferation marker. The present study was performed to determine the safety, distribution, radiation dosimetry, and initial brain tumor imaging of 11C-4DST in humans. Methods: Multiorgan biodistribution and radiation dosimetry of 11C-4DST were assessed in 3 healthy humans, who underwent 2-h whole-body PET scanning. Radiation dosimetry was estimated from the residence times of source organs using the OLINDA program. Six brain tumor patients underwent dynamic 11C-4DST scans with arterial blood sampling. These patients were also evaluated with 11C-methionine PET on the same day (n = 4) as, or 3 wk before (n = 2), 11C-4DST PET studies. Metabolites in plasma and urine samples were analyzed by high-performance liquid chromatography. Breakdown of the blood–brain barrier in tumor tissue was confirmed by gadolinium-enhanced T1-weighted MRI. Results: There were no serious adverse events in any subjects at any time during the study period. 11C-4DST PET demonstrated selective uptake in the bone marrow, which has a high rate of proliferation. In addition, high-level uptake was also seen in the liver. The highest absorbed organ dose was in the urinary bladder wall (17.6 muGy/MBq). The estimated effective dose for 11C-4DST was 4.2 muSv/MBq. 11C-4DST showed little uptake in normal brain tissues, resulting in low background activity for imaging of brain tumors. In contrast, 11C-4DST PET demonstrated rapid uptake in aggressive tumor masses, whereas no signal of 11C-4DST was seen in clinically stable disease in which 11C-methionine uptake was high. The distribution pattern of 11C-methionine in tumor regions was not always identical to that of 11C-4DST. Analysis of plasma samples by high-performance liquid chromatography indicated that more than 60% of the radioactivity was present as unchanged 11C-4DST at 20 min. Conclusion: The initial findings of the present study in a small group of patients indicated that 11C-4DST PET is feasible for imaging of brain tumors. Dosimetry and pharmacologic safety were acceptable at the dose required for adequate PET images. | |||||
書誌情報 |
Journal of Nuclear Medicine 巻 52, 号 8, p. 1322-1328, 発行日 2011-08 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0161-5505 |